Ruffer LLP Astrazeneca PLC Transaction History

Ruffer LLP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 10, 2023	SELL	$54.21 - $70.44 $12 Million - $15.6 Million	-221,057 Reduced 79.24%	57,930 $3.93 Million
Q3 2022 Nov 10, 2022	SELL	$53.02 - $135.75 $1.63 Million - $4.17 Million	-30,711 Reduced 9.92%	278,987 $15.3 Million
Q2 2022 Aug 05, 2022	SELL	$59.26 - $71.14 $76.7 Million - $92.1 Million	-1,294,931 Reduced 80.7%	309,698 $20.5 Million
Q1 2022 May 12, 2022	SELL	$55.72 - $67.12 $14.2 Million - $17.2 Million	-255,603 Reduced 13.74%	1,604,629 $106 Million
Q4 2021 Feb 04, 2022	SELL	$54.02 - $63.83 $6.03 Million - $7.12 Million	-111,564 Reduced 5.66%	1,860,232 $109 Million
Q3 2021 Nov 10, 2021	BUY	$55.56 - $60.79 $110 Million - $120 Million	1,971,796 New	1,971,796 $117 Million

1,361

475M

5.39M

3.75M

Ticker AZN
Exchange OTC
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 3,099,020,032
Market Cap $200B
Description
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, By...

Get notified when there are updates to the investment portfolio of Ruffer LLP, based on Form 13F filings with the SEC.

Stay updated on Ruffer LLP with notifications on news.